Items where Author is "Mills, M."

Item Type No Grouping

Article

HPR253 Drug development and launch timeline analysis across 6 high-income countries:from pivotal trial to HTA. Zaitceva, V and Tan, I and Mills, M. and Kanavos, P.

HTA117 Sentiment analysis of clinical evaluations in HTA:evidence from Canada, England, Scotland, Sweden, France, and Germany. Eaves, K. and Lin, R. and Alani, A. H. and Mills, M. and Kanavos, P.

HTA201 A quantitative assessment of the economic decision drivers outlined in HTA outcomes through stratification and sentiment analysis:evidence from Canada, England, Scotland, and Sweden. Eaves, K. and Lin, R. and Mills, M. and Kanavos, Panos

HTA354 Determinants of added benefit ratings in Germany:an econometric analysis of assessments from the Federal Joint Committee between 2012 and 2024. Tolkmitt, F. and Chavez, D. and Mills, M. and Kanavos, P.

HTA64 Leveraging machine learning for predicting health technology assessment outcomes. Lin, R. and Eaves, K. and Mills, M. and Kanavos, P.

PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process. Chavez, D. and Tolkmitt, F. and Mills, M. and Kanavos, P.